{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:34Z","timestamp":1793119414705,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"National Cancer Institute Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,10,14]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937\u00b1pembrolizumab in patients with advanced solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). Prior immunotherapy was permitted &gt;28\u2009days before study treatment. Patients received intravenous V937 on days 1, 3, and 5 (also on day 8 in part B) of the first 21-day cycle and on day 1 of subsequent cycles for eight cycles. Three ascending dose-escalation cohorts were studied. Dose-escalation proceeded if no dose-limiting toxicities (DLTs) occurred in cycle 1 of the previous cohort. In part B, patients also received pembrolizumab 200\u2009mg every 3 weeks from day 8 for 2 years; dose-expansion occurred at the highest-dose cohort. Serial biopsies were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No DLTs occurred in parts A (n=18) or B (n=85). Grade 3\u20135 treatment-related adverse events (AEs) were not observed in part A and were experienced by 10 (12%) patients in part B. The most frequent treatment-related AEs (any grade) in part B were fatigue (36%), pruritus (18%), myalgia (14%), diarrhea (13%), pyrexia (13%), influenza-like illness (12%), and nausea (12%). At the highest tested dose, median intratumoral V937 concentrations were 117,631 copies\/mL on day 8, cycle 1 in part A (n=6) and below the detection limit for most patients (86% (19\/22)) on day 15, cycle 1 in part B. Objective response rates were 6% (part A), 9% in the NSCLC dose-expansion cohort (n=43), and 20% in the urothelial cancer dose-expansion cohort (n=35).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intravenous V937+pembrolizumab had a manageable safety profile. Although V937 was detected in tumor tissue, in NSCLC and urothelial cancer, efficacy was not greater than that observed in previous studies with pembrolizumab monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02043665\">NCT02043665<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005007","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T11:30:15Z","timestamp":1674214215000},"page":"e005007","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02043665","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02043665","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-3465","authenticated-orcid":false,"given":"Charles M","family":"Rudin","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Professor of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardev S","family":"Pandha","sequence":"additional","affiliation":[{"name":"University of Surrey, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zibelman","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace L","family":"Akerley","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J","family":"Harrington","sequence":"additional","affiliation":[{"name":"The Royal Marsden\/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Oncology, Monash Health and Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Hill","sequence":"additional","affiliation":[{"name":"Tasman Oncology Research Ltd, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"O'Day","sequence":"additional","affiliation":[{"name":"John Wayne Cancer Institute, Providence St John's Health Center, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"Clay","sequence":"additional","affiliation":[{"name":"Medical Oncology, St. John of God Subiaco Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin M","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Surgery, St Vincent's Hospital Melbourne, The University of Melbourne, Fitzroy, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross R","family":"Jennens","sequence":"additional","affiliation":[{"name":"Epworth Healthcare, Richmond, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Gerber","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Ralph","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Institute of Oncology, St. James's University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Campbell","sequence":"additional","affiliation":[{"name":"Western Health, Sunshine Hospital, St Albans, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-2708","authenticated-orcid":false,"given":"Brendan D","family":"Curti","sequence":"additional","affiliation":[{"name":"Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime R","family":"Merchan","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine\/Sylvester Comprehensive Cancer Center, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Ren","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett V","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Guttman","sequence":"additional","affiliation":[{"name":"Practical Clinical, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-0831","authenticated-orcid":false,"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2025100309534758000_11.1.e005007.1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561372","article-title":"Remodeling of tumor immune microenvironment by oncolytic viruses","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"2025100309534758000_11.1.e005007.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100309534758000_11.1.e005007.3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.6.4736-4743.1997"},{"key":"2025100309534758000_11.1.e005007.4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S0022172400045228","article-title":"Experiments on the spread of colds. II. Studies in volunteers with coxsackievirus A21","volume":"63","author":"Buckland","year":"1965","journal-title":"J Hyg"},{"key":"2025100309534758000_11.1.e005007.5","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S56322"},{"key":"2025100309534758000_11.1.e005007.6","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT114","article-title":"Abstract CT114: the MITCI (phase 1B) study: a novel immunotherapy combination of intralesional coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment","volume":"77","author":"Curti","year":"2017","journal-title":"Cancer Res"},{"key":"2025100309534758000_11.1.e005007.7","doi-asserted-by":"crossref","unstructured":"Silk AW , O'Day SJ , Kaufman HL . Intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: updated results from the phase 1B Capra study. In: American Association for Cancer Research (AACR). Virtual, April 10-15, May 17-21, 2021.","DOI":"10.1158\/1538-7445.AM2021-CT139"},{"key":"2025100309534758000_11.1.e005007.8","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100309534758000_11.1.e005007.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4022"},{"key":"2025100309534758000_11.1.e005007.10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"2025100309534758000_11.1.e005007.11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0809-6"},{"key":"2025100309534758000_11.1.e005007.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100309534758000_11.1.e005007.13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100309534758000_11.1.e005007.14","doi-asserted-by":"crossref","unstructured":"Liauw WS , Chern B , Shafren DR . Phase 1, open-label, cohort study of CAVATAK (coxsackievirus A21) given intravenously to stage IV patients bearing ICAM-1 expressing solid tumors. In: EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics. Dublin, Ireland, November 9-12 2012.","DOI":"10.1016\/S0959-8049(12)72386-9"},{"key":"2025100309534758000_11.1.e005007.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2025100309534758000_11.1.e005007.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100309534758000_11.1.e005007.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025100309534758000_11.1.e005007.18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4502","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"JCO"},{"key":"2025100309534758000_11.1.e005007.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025100309534758000_11.1.e005007.20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100309534758000_11.1.e005007.21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1B study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025100309534758000_11.1.e005007.22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486"},{"key":"2025100309534758000_11.1.e005007.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100309534758000_11.1.e005007.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:53:53Z","timestamp":1759510433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-005007"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005007","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}